What Causes Methotrexate's Teratogenic Effects?
Methotrexate inhibits dihydrofolate reductase, disrupting folate metabolism essential for DNA synthesis and cell proliferation. This hits rapidly dividing embryonic cells hardest during organogenesis (weeks 3-8 post-conception), causing congenital anomalies.[1][2]
Key Teratogenic Effects Observed
Exposure in the first trimester links to a distinct pattern called methotrexate embryopathy or folate antagonism syndrome:
- Craniofacial defects: Cranial dysostosis, wide nasal bridge, hypertelorism (widely spaced eyes), low-set ears, micrognathia (small jaw).
- Limb abnormalities: Hypoplastic or absent digits, syndactyly, clubfoot.
- Growth issues: Intrauterine growth restriction, low birth weight.
- Central nervous system: Hydrocephalus, meningoencephalocele.
- Other: Cardiac septal defects, gastrointestinal atresias.[1][3][4]
Second- and third-trimester exposure raises risks of fetal growth restriction, preterm birth, and stillbirth, without the full embryopathy pattern.[2]
How Common Are These Effects?
In reported cases, first-trimester exposure yields malformation rates of 20-30%, with growth restriction in up to 70%. No safe dose exists in pregnancy; even low doses (e.g., for rheumatoid arthritis or ectopic pregnancy) carry risks.[1][5] Population data from registries show neural tube defects in ~7% of exposed fetuses.[4]
Timing of Exposure Matters
| Gestational Period | Primary Risks |
|--------------------|---------------|
| Pre-implantation (0-2 weeks) | Increased miscarriage, no malformations. |
| Organogenesis (3-8 weeks) | Full embryopathy (craniofacial/limb defects). |
| Later pregnancy (>8 weeks) | Growth restriction, functional deficits. |
Risk drops sharply after week 12, but long-term neurodevelopmental issues may persist.[2][3]
Use in Ectopic Pregnancy or Cancer
High-dose methotrexate treats ectopic pregnancy successfully in 85-95% of cases, but if pregnancy continues undiagnosed, teratogenic risks apply. Folic acid supplementation does not fully mitigate effects.[1][6] Category X drug—contraindicated in pregnancy.
Prevention and Management
Dual contraception required for reproductive-age patients on methotrexate. Pregnancy termination advised post-exposure. Folate antagonists like trimethoprim amplify risks.[2][5]
Long-Term Outcomes for Exposed Children
Survivors face developmental delays, learning disabilities, and hearing loss into childhood. Cardiac and skeletal issues may require surgery.[3][4]
Sources
[1] ACOG Practice Bulletin: Medical Management of Ectopic Pregnancy
[2] FDA Label: Methotrexate
[3] Donnenfeld et al., Teratology 1994: Methotrexate Exposure in Utero
[4] Kozlowski et al., Birth Defects Res 2017: Review of Methotrexate Embryopathy
[5] REMS Program: Methotrexate
[6] American College of Rheumatology Guidelines: Reproductive Health